ResMed Inc.
NYSE:RMDMedical - Devices
+$1.58 today
- Market cap
- $34.12B
- Beta
- 0.78
- P/E (TTM)
- 18.1
- EPS (TTM)
- $10.37
- Dividend yield
- 1.28%
Volume 1.22M
Average 1.32M
RMD EBITDA Margin
EBITDA as a percentage of revenue.
ResMed Inc.NYSE: RMD
EBITDA Margin · Q4 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to 34.4%
EBITDA Margin was 34.4% in Q4 FY2026, down 5.1 pp from a year earlier. On a trailing-twelve-month basis it was 38.3%, up 1.0 pp year over year. Over 3 fiscal years it widened by 5.9 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2026 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 22 analysts of 41.5% for the fiscal year ending Jun 2027, up from 38.1% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 34.4%-6.4 pp QoQ
- Last fiscal yearJun 2026
- 38.1%+0.9 pp YoY
- LTMJun 2026
- 38.3%+1.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.1 pp | -1.1 pp | +4.0 pp |
| 1 year | +0.9 pp | +3.4 pp | +2.5 pp |
| 3 years | +5.9 pp | +2.3 pp | -3.6 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 38.1%
- Year-over-year change
- +0.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 38.1% | +0.9pp |
| FY2025 | 2025-06-30 | 37.2% | +4.4pp |
| FY2024 | 2024-06-30 | 32.7% | +0.5pp |
| FY2023 | 2023-06-30 | 32.2% | -0.7pp |
| FY2022 | 2022-06-30 | 32.9% | — |
EBITDA Margin vs competitors
How RMD compares with its peers on the latest reported figures
- RMD's LTM Jun 2026 EBITDA Margin of 38.3% is the highest of the 9 companies compared; the peer median is 18.9%.
- Its year-over-year change of +1.0 pp is the 4th highest of 9, against a peer median of -0.4 pp.
- Over three fiscal years its change of +5.9 pp compares with a peer median of +5.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 38.3% | +1.0 pp | +5.9 pp | |
| LTM Sep 2026 | 36.2% | -2.8 pp | +7.9 pp | |
| LTM Jun 2026 | 27.6% | +2.2 pp | +3.8 pp | |
| LTM Jul 2026 | 27.3% | +0.0 pp | -0.9 pp | |
| LTM Mar 2026 | 20.6% | +3.4 pp | +9.2 pp | |
| LTM Jun 2026 | 17.3% | +6.7 pp | +14.2 pp | |
| LTM Jun 2026 | 15.2% | -4.0 pp | +1.1 pp | |
| LTM Jun 2026 | 9.2% | -0.9 pp | +18.7 pp | |
| LTM Jun 2026 | -6.1% | -25.9 pp | -11.0 pp | |
| Peer median (excluding RMD) | 18.9% | -0.4 pp | +5.9 pp | |
Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 3.58B | 4.22B | 4.69B | 5.15B | 5.65B |
| Cost of Revenue | 1.55B | 1.87B | 2.03B | 2.09B | 2.2B |
| Gross Profit | 2.02B | 2.36B | 2.66B | 3.05B | 3.45B |
| Gross Margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| Research & Development | 253.58M | 287.64M | 307.53M | 331.28M | 378.29M |
| Selling, General & Admin | 739.37M | 874M | 917.14M | 991.02M | 1.12B |
| Operating Expenses | 1.02B | 1.22B | 1.34B | 1.37B | 1.54B |
| Depreciation & Amortization | 193.84M | 197.56M | 216.21M | 235.81M | 244.15M |
| EBITDA | 1.18B | 1.36B | 1.53B | 1.91B | 2.15B |
| EBITDA Margin | 32.9% | 32.2% | 32.7% | 37.2% | 38.1% |
| Operating Income | 1B | 1.13B | 1.32B | 1.69B | 1.91B |
| Operating Margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.31M | 47.38M | 45.71M | 12.61M | 0 |
| Other Income / Expenses | (39.8M) | (30.21M) | (55.1M) | (7.8M) | 10.96M |
| Income Before Tax | 960.48M | 1.1B | 1.26B | 1.68B | 1.92B |
| Pre-Tax Margin | 26.8% | 26.1% | 27.0% | 32.6% | 34.0% |
| Income Tax Expense | 181.05M | 204.11M | 243.85M | 276.84M | 396.12M |
| Net Income | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
| Net Margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| EPS (Basic) | 5.34 | 6.12 | 6.94 | 9.55 | 10.44 |
| EPS (Diluted) | 5.30 | 6.09 | 6.92 | 9.51 | 10.40 |
| Weighted Avg Shares | 146.07M | 146.77M | 147.02M | 146.72M | 144.71M |
| Weighted Avg Shares (Diluted) | 147.04M | 147.46M | 147.55M | 147.34M | 144.98M |
ResMed Inc.
NYSE:RMD
Intrinsic Alpha fair value
Locked
Current Price
$242.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.